CR10273A - "anticuerpos anti-5t4 y usos de los mismos" - Google Patents

"anticuerpos anti-5t4 y usos de los mismos"

Info

Publication number
CR10273A
CR10273A CR10273A CR10273A CR10273A CR 10273 A CR10273 A CR 10273A CR 10273 A CR10273 A CR 10273A CR 10273 A CR10273 A CR 10273A CR 10273 A CR10273 A CR 10273A
Authority
CR
Costa Rica
Prior art keywords
antibodies
same
antibody
preparing
methods
Prior art date
Application number
CR10273A
Other languages
English (en)
Inventor
Erwin R Boghaert
Nitin K Damle
Philip Ross Hamann
Kiran Khandke
Arthur Kunz
Kimberly A Marquette
Lioudmile Tchistiakova
Davinder Gill
Kodangattil Sreekumar
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38445207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10273(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR10273A publication Critical patent/CR10273A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Anticuerpos antiI-5T4, conjugados de anticuerpo anti-5t4/farmaco, y metodos para preparar y usar los mismos.
CR10273A 2006-03-10 2008-09-05 "anticuerpos anti-5t4 y usos de los mismos" CR10273A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78134606P 2006-03-10 2006-03-10
US89124807P 2007-02-23 2007-02-23

Publications (1)

Publication Number Publication Date
CR10273A true CR10273A (es) 2008-11-26

Family

ID=38445207

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10273A CR10273A (es) 2006-03-10 2008-09-05 "anticuerpos anti-5t4 y usos de los mismos"

Country Status (29)

Country Link
US (5) US8044178B2 (es)
EP (3) EP2368914B1 (es)
JP (1) JP5523824B2 (es)
KR (2) KR101443752B1 (es)
CN (1) CN101437850B (es)
AR (1) AR059809A1 (es)
AU (1) AU2007226696C1 (es)
BR (1) BRPI0708771B8 (es)
CA (1) CA2645097C (es)
CR (1) CR10273A (es)
DK (2) DK1994055T3 (es)
EC (1) ECSP088733A (es)
ES (2) ES2498517T3 (es)
GT (1) GT200800181A (es)
IL (2) IL193986A (es)
MX (1) MX2008011492A (es)
MY (1) MY148763A (es)
NO (1) NO20083891L (es)
NZ (2) NZ571208A (es)
PA (1) PA8718601A1 (es)
PE (1) PE20080119A1 (es)
PL (1) PL1994055T3 (es)
PT (1) PT1994055E (es)
SA (1) SA07280101B1 (es)
SG (1) SG170091A1 (es)
SI (1) SI1994055T1 (es)
TW (2) TWI409277B (es)
WO (1) WO2007106744A2 (es)
ZA (1) ZA200808075B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1978985A2 (en) * 2005-12-23 2008-10-15 Board Of Regents Of The University Of Texas System Anti-hyperproliferative therapies targeting hdgf
WO2007106744A2 (en) * 2006-03-10 2007-09-20 Wyeth Anti-5t4 antibodies and uses thereof
ATE536374T1 (de) 2006-09-01 2011-12-15 Therapeutic Human Polyclonals Inc Erhöhte expression von humanem oder humanisiertem immunglobulin bei nicht-humanen transgenen tieren
ES2405605T3 (es) 2009-03-27 2013-05-31 Wyeth Llc Células iniciadoras de tumores y procedimientos de uso de las mismas
GB0918383D0 (en) 2009-10-20 2009-12-02 Cancer Rec Tech Ltd Prognostic,screening and treatment methods and agents for treatment of metastasis and inflammation
WO2011127141A1 (en) * 2010-04-07 2011-10-13 Abbott Laboratories TNF-α BINDING PROTEINS
ES2683953T3 (es) * 2011-02-07 2018-09-28 Aggamin Llc Procedimientos y sistemas para tratar o prevenir trastornos hipertensivos gestacionales
PH12013501942A1 (en) * 2011-04-01 2019-11-29 Wyeth Llc Antibody-drug conjugates
US9505847B2 (en) 2011-08-22 2016-11-29 Cnj Holdings Inc Clostridium difficile antibodies
WO2013041687A1 (en) 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5t4 and cd3
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
MX361058B (es) 2012-01-24 2018-11-23 Pfizer Método para detectar células tumorales circulantes 5t4-positivas y métodos de diagnóstico de cáncer 5t4-positivo en un sujeto mamífero.
KR20150093770A (ko) 2012-12-12 2015-08-18 베스쿨럭스 인코포레이티드 치료적 ｃｄ４７ 항체
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
WO2014137931A1 (en) * 2013-03-06 2014-09-12 Imaginab, Inc. Antigen binding constructs to 5t4
WO2014160183A1 (en) 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
EP3010939A2 (en) * 2013-06-17 2016-04-27 Asana BioSciences, LLC 5t4-targeted immunofusion molecule and methods
ES2726850T3 (es) 2013-10-11 2019-10-09 Mersana Therapeutics Inc Conjugados de proteína-polímero-fármaco
KR102355745B1 (ko) 2013-10-11 2022-01-26 아사나 바이오사이언시스 엘엘씨 단백질-폴리머-약물 접합체
EP3065780A1 (en) 2013-11-04 2016-09-14 Pfizer Inc. Anti-efna4 antibody-drug conjugates
WO2015155345A1 (en) * 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
RU2670157C2 (ru) 2014-05-22 2018-10-18 Синтон Байофармасьютикалс Б. В. Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc
NZ726514A (en) * 2014-05-29 2019-01-25 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
CN106922148B (zh) 2014-07-29 2021-10-15 瑟勒提斯公司 用于癌症免疫疗法的ror1(ntrkr1)特异性的嵌合抗原受体
WO2016016343A1 (en) 2014-07-31 2016-02-04 Cellectis Ror1 specific multi-chain chimeric antigen receptor
CA2959694C (en) * 2014-09-04 2023-11-21 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
EP3247392A1 (en) * 2015-01-22 2017-11-29 Prothena Biosciences Limited Antibodies recognizing medin
WO2016185035A1 (en) 2015-05-20 2016-11-24 Cellectis Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy
UA126146C2 (uk) 2015-09-18 2022-08-25 Арч Онколоджі, Інк. Терапевтичне антитіло до cd47
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
WO2017089447A1 (en) * 2015-11-24 2017-06-01 Synthon Biopharmaceuticals B.V. Anti-5t4 antibodies and antibody-drug conjugates
CN110698560B (zh) * 2015-12-24 2021-11-26 凯惠科技发展(上海)有限公司 一种tpbg抗体及其制备方法、其偶联物和应用
SG10201912556VA (en) * 2016-07-20 2020-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
CN108084265B (zh) * 2016-11-23 2021-07-02 复旦大学 特异性结合人的5t4抗原的全人源单域抗体及其应用
CN108285487B (zh) * 2017-01-08 2021-02-19 浙江昭华生物医药有限公司 抗5t4抗体-药物偶联物及其应用
AU2018224094B2 (en) 2017-02-24 2025-04-17 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
JP7277388B2 (ja) * 2017-03-15 2023-05-18 オックスフォード バイオメディカ（ユーケー）リミテッド 方法
EP3608335A4 (en) * 2017-04-05 2020-04-29 XDCExplorer (Shanghai) Co., Ltd. HUMANIZED ANTI-TPBG ANTIBODY, PRODUCTION METHOD THEREFOR, CONJUGATE THEREOF AND APPLICATIONS
CN120607624A (zh) 2017-04-11 2025-09-09 因荷布瑞克斯生物科学公司 具有受限cd3结合的多特异性多肽构建体及其使用方法
EP3634476A4 (en) * 2017-06-06 2021-06-02 The Regents of The University of California HUMANIZED ANTI-N-CADHERIN ANTIBODIES AND USES THEREOF
JP7369113B2 (ja) 2017-07-20 2023-10-25 アプティーボ リサーチ アンド デベロップメント エルエルシー 癌胎児性抗原結合タンパク質、関連する化合物および方法
EP3717021A1 (en) 2017-11-27 2020-10-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
EP3727463A1 (en) 2017-12-21 2020-10-28 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
CN108187065B (zh) * 2017-12-29 2023-04-28 广东众生药业股份有限公司 抗5t4抗体与美登素衍生物dm4偶联复合物及制备方法和用途
US11965188B2 (en) 2018-01-03 2024-04-23 Palleon Pharmaceuticals Inc. Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
CN111971298B (zh) 2018-03-12 2025-06-20 健玛保 抗体
AU2019251488B2 (en) 2018-04-11 2026-02-12 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs having constrained CD3 binding and related methods and uses
US12195533B2 (en) 2018-07-24 2025-01-14 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020077257A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
EP3873534A1 (en) 2018-10-29 2021-09-08 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
US20230257479A1 (en) 2019-09-12 2023-08-17 Genmab A/S Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
JP7789002B2 (ja) 2020-01-29 2025-12-19 インヒブルクス バイオサイエンシズ インコーポレイテッド Ｃｄ２８シングルドメイン抗体ならびにその多価および多重特異性の構築物
CN115279403A (zh) 2020-02-21 2022-11-01 宏观基因有限公司 Cd137结合分子及其用途
US20220251239A1 (en) * 2020-10-22 2022-08-11 Actinium Pharmaceuticals, Inc. Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
US20220288244A1 (en) * 2020-10-22 2022-09-15 Actinium Pharmaceuticals, Inc. Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
WO2022087416A1 (en) * 2020-10-22 2022-04-28 Actinium Pharmaceuticals, Inc. Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
AU2022206264A1 (en) * 2021-01-06 2023-07-20 Palleon Pharmaceuticals Inc. Anti-pd-l1 antibodies and fusion proteins thereof
EP4482876A1 (en) * 2022-02-21 2025-01-01 Concept to Medicine Biotech Co., Ltd. Anti-5t4 antibodies and uses thereof
EP4596536A1 (en) 2022-09-30 2025-08-06 Shanghai de Novo Pharmatech Co., Ltd. Benzazepine derivative, conjugate containing same, and use thereof
EP4353220A1 (en) * 2022-10-12 2024-04-17 Pierre Fabre Medicament Use of a liquid aqueous composition for solubilization and stabilization of an antibody-drug conjugate
CN116715773B (zh) * 2023-02-28 2024-03-01 星奕昂(上海)生物科技有限公司 一种靶向5t4的抗体及其应用
KR20250158033A (ko) * 2023-03-08 2025-11-05 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 항-5t4 항체 및 이의 용도
EP4683673A2 (en) * 2023-03-22 2026-01-28 Salubris Biotherapeutics, Inc. Anti-5t4 antigen binding domains, antibody-drug conjugates and methods of use thereof
EP4692126A1 (en) * 2023-04-03 2026-02-11 Sound Biopharmaceuticals Co. Ltd. Anti-5t4 antibody and use thereof
UY40783A (es) 2023-06-12 2024-12-31 Amgen Inc Proteínas de unión a agonistas del receptor beta de linfotoxina

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5108912A (en) 1987-01-30 1992-04-28 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5037651A (en) 1987-01-30 1991-08-06 American Cyanamid Company Dihydro derivatives of LL-E33288 antibiotics
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
AU3353989A (en) * 1988-03-04 1989-09-22 Cancer Research Campaign Technology Limited Improvements relating to antigens
US5869053A (en) 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
KR0162259B1 (ko) 1989-12-05 1998-12-01 아미 펙터 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
GB9116610D0 (en) 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
ZA955642B (en) 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5952329A (en) 1996-01-23 1999-09-14 The General Hospital Corporation Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors
IL132596A0 (en) * 1997-06-04 2001-03-19 Oxford Biomedica Ltd Vector
EP1036091B2 (en) 1998-11-18 2008-03-26 Oxford Biomedica (UK) Limited 5t4 tumour-associated antigen for use in tumour immunotherapy
GB2370573A (en) 1998-11-18 2002-07-03 Oxford Biomedica Ltd Poxviral vectors
GB2378704B (en) 1998-11-18 2003-05-07 Oxford Biomedica Ltd Uses of 5t4 antigen
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
EP1396543A3 (en) * 1999-07-08 2004-03-31 Research Association for Biotechnology Primers for synthesizing full length cDNA clones and their use
WO2001062299A2 (en) 2000-02-28 2001-08-30 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
CN1468250A (zh) 2000-08-03 2004-01-14 ��ķһ����˹��̹ 在转基因动物中产生人源化抗体
WO2002038612A2 (en) * 2000-11-13 2002-05-16 Oxford Biomedica (Uk) Limited Canine and feline tumour-associated antigen 5t4
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
WO2002100326A2 (en) 2001-05-01 2002-12-19 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
GB0203419D0 (en) * 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
SG187991A1 (en) 2002-05-02 2013-03-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
CA2571743A1 (en) 2004-06-30 2006-01-12 International Bioimmune Systems, Inc. Humanized monoclonal antibody 31.1 as an anticancer agent
MX2007002826A (es) 2004-09-10 2007-04-27 Wyeth Corp Anticuerpos anti-5t4 humanizados y conjugados de anticuerpos anti-5t4/caliqueamicina.
EP1828251B1 (en) * 2004-10-05 2012-09-26 Janssen Alzheimer Immunotherapy Methods and compositions for improving recombinant protein production
WO2007106744A2 (en) 2006-03-10 2007-09-20 Wyeth Anti-5t4 antibodies and uses thereof
EP2560645B1 (en) 2010-04-21 2016-07-13 Syntarga B.V. Conjugates of cc-1065 analogs and bifunctional linkers
PH12013501942A1 (en) * 2011-04-01 2019-11-29 Wyeth Llc Antibody-drug conjugates

Also Published As

Publication number Publication date
AR059809A1 (es) 2008-04-30
AU2007226696B2 (en) 2013-08-29
AU2007226696A1 (en) 2007-09-20
WO2007106744A2 (en) 2007-09-20
US20070231333A1 (en) 2007-10-04
ES2498517T3 (es) 2014-09-24
CA2645097A1 (en) 2007-09-20
US9902771B2 (en) 2018-02-27
DK1994055T3 (da) 2014-08-25
KR20130018980A (ko) 2013-02-25
ECSP088733A (es) 2008-10-31
PE20080119A1 (es) 2008-03-04
EP1994055B1 (en) 2014-07-02
BRPI0708771B1 (pt) 2019-10-22
AU2007226696C1 (en) 2016-02-04
KR101443752B1 (ko) 2014-09-26
WO2007106744A3 (en) 2007-11-29
JP2009529578A (ja) 2009-08-20
CA2645097C (en) 2019-09-17
BRPI0708771A2 (pt) 2011-06-14
KR101264216B1 (ko) 2013-05-31
NZ571208A (en) 2011-12-22
SA07280101B1 (ar) 2011-10-03
CN101437850B (zh) 2013-10-09
EP2368914B1 (en) 2019-01-02
PL1994055T3 (pl) 2015-02-27
TW201335189A (zh) 2013-09-01
HK1121473A1 (en) 2009-04-24
TWI421257B (zh) 2014-01-01
EP1994055A2 (en) 2008-11-26
IL193986A (en) 2015-08-31
WO2007106744A8 (en) 2008-10-02
US20180162937A1 (en) 2018-06-14
PA8718601A1 (es) 2009-05-15
SI1994055T1 (sl) 2014-08-29
US8044178B2 (en) 2011-10-25
US20160185859A1 (en) 2016-06-30
EP3539989A1 (en) 2019-09-18
MX2008011492A (es) 2008-09-22
NO20083891L (no) 2008-12-03
SG170091A1 (en) 2011-04-29
ES2712942T3 (es) 2019-05-16
TWI409277B (zh) 2013-09-21
MY148763A (en) 2013-05-31
KR20080106345A (ko) 2008-12-04
PT1994055E (pt) 2014-09-15
ZA200808075B (en) 2012-03-28
EP2368914A1 (en) 2011-09-28
TW200804424A (en) 2008-01-16
DK2368914T3 (en) 2019-03-04
RU2008137074A (ru) 2010-04-20
BRPI0708771B8 (pt) 2021-05-25
JP5523824B2 (ja) 2014-06-18
US20120064600A1 (en) 2012-03-15
US20140308302A1 (en) 2014-10-16
IL193986A0 (en) 2011-08-01
GT200800181A (es) 2010-05-25
US8759495B2 (en) 2014-06-24
IL240245A0 (en) 2015-09-24
NZ596295A (en) 2013-01-25
CN101437850A (zh) 2009-05-20
IL240245A (en) 2017-05-29

Similar Documents

Publication Publication Date Title
CR10273A (es) "anticuerpos anti-5t4 y usos de los mismos"
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
SV2007002227A (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637
CY1119102T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεισαυτων
NO20083127L (no) Fremgangsmater og preparater for malretting av polyubiquitin
NO20085396L (no) Antistoffer og immunkonjugater, og anvendelser derav
CY1118343T1 (el) Αντισωματα συνδεσης twεακ
MX2020001497A (es) Sintesis de gamma-carbolinas fusionadas con heterociclo substituido.
BRPI0510674A (pt) variantes fc otimizadas
CR10372A (es) Anticuerpos anti-tat226 e inmunoconjugados
PE20150891A1 (es) Anticuerpos anti-receptor de il-13 alfa 2 y conjugados de anticuerpo farmaco
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
LT3656793T (lt) Monokloniniai antikūnai prieš klaudiną-18, skirti vėžio gydymui
AR063640A1 (es) Anticuerpos agonistas de trkb y usos de los mismos
CL2008001258A1 (es) Kit de vacuna que comprende al menos nueve conjugados de sacaridos de antgenos hb o hib, donde al menos 2-7 son con la proteina transportadora crm, siendo dicho kit adecuado para usar en su calendario de inmunizacion primaria; vacuna combinada adecuada para la inmunizacion primaria.
EA200900767A1 (ru) Антагонистические антитела против ephb3
DK3199180T3 (da) Epha3-antistoffer til behandlingen af faste tumorer
CL2009001487A1 (es) Procesos para la síntesis convergente de los derivados de caliqueamicina. (divisional de sol. 442-2007)
ECSP11011190A (es) Anticuerpos monoclonales anti-rhd
EA200870148A1 (ru) Производные сулиндака, их применение и получение
DK1899377T3 (da) Humaniserede antistoffer, der er specifikke for NOGO-A, og farmaceutiske anvendelser deraf.
TR201902670T4 (tr) Anti-5t4 antikorları ve bunların kullanımları.
CR20140126A (es) Anticuerpos anti-tat226 e inmunoconjugados
TH148531A (th) วิธีการและองค์ประกอบสำหรับกำหนดเป้าหมายพอลิยูไบควิทิน

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)